| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by (used in) investing activities | 153,647 | 92,800 |
| Proceeds from issuance of stock from employee benefit plans | 1,039 | 265 |
| Net cash provided by financing activities | 1,039 | 265 |
| Net increase in cash and cash equivalents | 7,681 | -5,312 |
| Cash and cash equivalents at beginning of period | 28,356 | - |
| Cash and cash equivalents at end of period | 36,037 | - |
Celldex Therapeutics, Inc. (CLDX)
Celldex Therapeutics, Inc. (CLDX)